Study Overview
Zeus Hygia Lifesciences, an innovator in nutraceutical solutions, released a press statement on August 14, 2026 announcing the publication of a clinical trial evaluating Metaberine®, its bio‑optimised berberine formulation developed with proprietary BioSOLVE® Technology. The trial was a randomized, double‑blind, placebo‑controlled crossover study involving 36 healthy adults whose fasting glucose levels ranged from 100 to 125 mg/dL, indicating metabolic risk. Participants received either Metaberine® 200 mg or a matching placebo once daily for 14 days, followed by a seven‑day washout period before crossing over to the alternate arm.
Key Findings
The study demonstrated statistically significant improvements in several metabolic markers for the Metaberine® arm. Fasting glucose decreased by 9.08 mg/dL compared with a 1.36 mg/dL reduction in the placebo group. Measures of glucose exposure and peak glucose concentrations also showed significant declines. Fasting glucagon‑like peptide‑1 (GLP‑1) increased by 29 % and post‑prandial GLP‑1 rose by 22 % relative to baseline. Lipid parameters improved: total cholesterol and low‑density lipoprotein cholesterol (LDL‑C) fell, while high‑density lipoprotein cholesterol (HDL‑C) increased. The trial achieved 100 % participant retention and reported no supplement‑related adverse events.
Safety, Publication and Commercial Availability
The authors concluded that the results support further investigation of bio‑optimised berberine in metabolic health applications. The full study is published in the International Journal of Clinical Trials (link provided). According to CEO and Co‑founder Dr. Arunkanth Krishnakumar, the findings illustrate that Metaberine® can deliver meaningful metabolic benefits at a low daily dose, overcoming the high‑dose limitation of conventional berberine formulations. Metaberine® is positioned for B2B use across nutraceuticals, dietary supplements, functional foods and beverages, over‑the‑counter health products, pharmaceuticals, and contract manufacturing, enabling partners to develop next‑generation metabolic wellness solutions.